ectd
(2)
Celegence Found the Unsexy AI Business: Fixing the Paperwork That Keeps Medicine on the Market
Two sisters started with regulatory services, watched their own writers wrestle with hundred-page reports, and built software around the bottlenecks. The result is a useful playbook for enterprise AI: begin with paid work, reject the clever features that cannot be checked, and automate only what experts can defend.
Weave Bio
Weave Bio is a San Francisco-based, AI-native software company that automates the regulatory paperwork behind drug development. Its platform ingests preclinical and clinical study data and drafts submission-ready documents - INDs, investigator's brochures, clinical study reports and health-authority responses - in eCTD-ready format, cutting timelines that once took months down to hours while keeping human reviewers in the loop. Founded in 2022, Weave serves biotech, pharma, CROs and regulatory consultants, and raised a $20M Series A in October 2025 to bring total funding to roughly $36M.